See more : Alphabet Inc. (GOOGL.SW) Income Statement Analysis – Financial Results
Complete financial analysis of Sight Sciences, Inc. (SGHT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sight Sciences, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Jetmall Spices and Masala Limi (JETMALL.BO) Income Statement Analysis – Financial Results
- Refined Metals Corp. (RMC.CN) Income Statement Analysis – Financial Results
- SSPN Finance Limited (SSPNFIN.BO) Income Statement Analysis – Financial Results
- KELWYNN INC DEL (KELN) Income Statement Analysis – Financial Results
- American Equity Investment Life Holding Company (AEL-PB) Income Statement Analysis – Financial Results
Sight Sciences, Inc. (SGHT)
About Sight Sciences, Inc.
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 81.06M | 71.33M | 48.96M | 27.64M | 23.35M | 7.53M |
| Cost of Revenue | 11.88M | 12.36M | 8.61M | 9.21M | 6.54M | 2.34M |
| Gross Profit | 69.18M | 58.97M | 40.35M | 18.43M | 16.80M | 5.19M |
| Gross Profit Ratio | 85.34% | 82.67% | 82.41% | 66.68% | 71.97% | 68.95% |
| Research & Development | 17.56M | 22.86M | 15.63M | 8.87M | 8.12M | 5.43M |
| General & Administrative | 106.79M | 117.47M | 74.09M | 40.95M | 30.92M | 13.06M |
| Selling & Marketing | 2.10M | 2.60M | 2.10M | 800.00K | 1.80M | 1.00M |
| SG&A | 108.89M | 120.07M | 76.19M | 41.75M | 32.72M | 14.06M |
| Other Expenses | 0.00 | 2.23M | -6.93M | -71.00K | -35.00K | 0.00 |
| Operating Expenses | 126.45M | 142.92M | 91.82M | 50.62M | 40.84M | 19.49M |
| Cost & Expenses | 138.33M | 155.29M | 100.43M | 59.83M | 47.39M | 21.83M |
| Interest Income | 0.00 | 4.47M | 4.37M | 30.00K | 174.00K | 1.00K |
| Interest Expense | 5.41M | 4.47M | 4.37M | 2.40M | 1.96M | 0.00 |
| Depreciation & Amortization | 614.00K | 1.25M | 1.20M | 1.12M | 432.00K | 63.00K |
| EBITDA | -49.42M | -80.48M | -57.21M | -31.68M | -23.47M | -14.23M |
| EBITDA Ratio | -60.96% | -114.58% | -119.30% | -114.60% | -101.10% | -189.02% |
| Operating Income | -57.27M | -83.95M | -51.48M | -32.19M | -24.04M | -14.30M |
| Operating Income Ratio | -70.66% | -117.70% | -105.15% | -116.45% | -102.96% | -189.87% |
| Total Other Income/Expenses | 1.84M | -2.24M | -11.29M | -2.44M | -1.82M | 1.00K |
| Income Before Tax | -55.44M | -86.20M | -62.77M | -34.63M | -25.86M | -14.30M |
| Income Before Tax Ratio | -68.39% | -120.84% | -128.22% | -125.30% | -110.76% | -189.85% |
| Income Tax Expense | 110.00K | 47.00K | 188.00K | 61.00K | 8.00K | -6.00K |
| Net Income | -55.55M | -86.24M | -62.96M | -34.69M | -25.87M | -14.29M |
| Net Income Ratio | -68.53% | -120.90% | -128.61% | -125.52% | -110.80% | -189.77% |
| EPS | -1.14 | -1.80 | -1.33 | -0.74 | -0.55 | -0.44 |
| EPS Diluted | -1.14 | -1.80 | -1.33 | -0.74 | -0.55 | -0.44 |
| Weighted Avg Shares Out | 48.63M | 47.85M | 47.50M | 46.77M | 46.77M | 32.20M |
| Weighted Avg Shares Out (Dil) | 48.63M | 47.85M | 47.50M | 46.77M | 46.77M | 32.20M |
Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference
MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that...
Sight Sciences, Inc. (SGHT) Q3 2024 Earnings Call Transcript
Sight Sciences, Inc. (NASDAQ:SGHT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matt Link...
Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Misses Revenue Estimates
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.27 per share a year ago.
Sight Sciences to Report Third Quarter Financial Results on November 7, 2024
MENLO PARK, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it...
Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial
The study found improvements in reading speed, vision-related quality of life, and suggested potential benefits of an interventional approach for patients with dry eye disease The study found improvements in reading speed, vision-related quality of life, and suggested potential benefits...
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
MENLO PARK, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that...
Sight Sciences, Inc. (SGHT) Q2 2024 Earnings Call Transcript
Sight Sciences, Inc. (NASDAQ:SGHT ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matthew Link...
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.30 per share a year ago.
Sight Sciences to Report Second Quarter Financial Results on August 1, 2024
MENLO PARK, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it...
Sight Sciences Announces the Release of its First Sustainability Report
The Sustainability Report provides data for 2021 through 2023 on the Company's environmental, social, and governance initiatives The Sustainability Report provides data for 2021 through 2023 on the Company's environmental, social, and governance initiatives
Source: https://incomestatements.info
Category: Stock Reports